Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Debt (2018 - 2021)

Rein Therapeutics (RNTX) has disclosed Non-Current Debt for 3 consecutive years, with $55000.0 as the latest value for Q1 2021.

  • Quarterly Non-Current Debt changed N/A to $55000.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $55000.0 through Mar 2021, changed N/A year-over-year, with the annual reading at $219000.0 for FY2020, N/A changed from the prior year.
  • Non-Current Debt for Q1 2021 was $55000.0 at Rein Therapeutics, down from $219000.0 in the prior quarter.
  • The five-year high for Non-Current Debt was $5.3 million in Q4 2018, with the low at $55000.0 in Q1 2021.
  • Average Non-Current Debt over 3 years is $2.1 million, with a median of $336000.0 recorded in 2020.